Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
Crossref DOI link: https://doi.org/10.1007/s10549-014-3238-6
Published Online: 2014-12-30
Published Print: 2015-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Clemens, Michael R.
Gladkov, Oleg A.
Gartner, Elaina
Vladimirov, Vladimir
Crown, John
Steinberg, Joyce
Jie, Fei
Keating, Anne
License valid from 2014-12-30